A 26-week Treatment, Multicenter, Randomized, Parallel Group, Blinded Study to Assess the Efficacy and Safety of QVA149 (110/50 microg q.d.) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium Plus Formoterol as an Active Control

Trial Profile

A 26-week Treatment, Multicenter, Randomized, Parallel Group, Blinded Study to Assess the Efficacy and Safety of QVA149 (110/50 microg q.d.) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium Plus Formoterol as an Active Control

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Glycopyrrolate/indacaterol (Primary) ; Formoterol; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms QUANTIFY
  • Sponsors Novartis
  • Most Recent Events

    • 02 Apr 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 16 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 10 Nov 2012 New source identified and integrated (European Clinical Trials Database record: EudraCT2011-004870-26).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top